BRCA1 and pachyonychia congenita: In line with this evidence, among the tumors reported in the analyzed DH BRCA1/2 families, the most frequent was OC (21.4%), followed by BC, prostate cancer (PC), and CC, with a percentage of 14.3%, and bBC, breast and ovarian cancer (BOC), bladder cancer (BLC), leukemia (LEU), and laryngeal cancer (LAC), with a percentage of 7.1% (Figure 6).